WITTEN, Germany--(BUSINESS WIRE)--The SastoMed GmbH has announced that the British National Health Service (NHS) has taken the wound spray Granulox licensed by Sangui to SastoMed GmbH on the list of reimbursable products under a discrete category (NHS Drug Tariff Part IX) effective October 01, 2016. The NHS provides to each resident of the UK medical care in the primary (general practitioner GP) and secondary level (hospitals) free of charge. Furthermore, in a declaration recently published the Scottish Health Technologies Group (SHTG - a division of NHSScottland) has clearly recommended the application of Granulox to all doctors working for NHSScottland because of Granulox’ efficacy and marked cost savings of several thousand British pounds proved by several studies.
Michael Sander, Managing Director of SastoMed GmbH commented: "InFirst Healthcare as our partner in the UK, has done an excellent job. Because of the convincing data submitted a worldwide respected and efficient health care system such as the NHS has not only appreciated the significant improvement in the quality of life for millions of patients suffering from chronic wounds, but also confirmed the significant cost reduction potential by using Granulox. We see this as a breakthrough success, which will integrated Granulox in modern wound treatment system not only in Great Britain. In parallel InFirst is working hard on the approval for the US market - even for that the extensive data from England constitute an important basis ".
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.